Efficacy and safety of ezetimibe in young children with familial hypercholesterolemia.
Completed
- Conditions
- Familial hypercholesterolemia
- Registration Number
- NL-OMON25426
- Lead Sponsor
- Academic Medical Centre (AMC), Department of Vascular Medicine
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 70
Inclusion Criteria
1. Males or females;
2. Aged 8-14 years;
Exclusion Criteria
1. Homozygous familial hypercholesterolemia;
2. Diseases that cause a secondary increase in LDL-C, such as diabetes mellitus, anorexia nervosa and renal, hepatic or thyroid disease;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint will be the efficacy towards LDL-C levels and the safety of 10 mg ezetimibe.
- Secondary Outcome Measures
Name Time Method Secondary endpoint will be the effect of 10 mg ezetimibe on inflammatory markers and plant sterols in plasma.